Ceftazidime-avibactam drives mutations, insertion, or overexpression in bla

Jun Li, Zhaojun Liu, Haolan Wang, Yubing Xia, Yongmei Hu, Haichen Wang, Fengjun Xia, Mingxiang Zou

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Targeting KPC-ProducingMicroorganisms · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jun LiDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Zhaojun LiuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Haolan WangDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Yubing XiaDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Yongmei HuDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Haichen WangDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Fengjun XiaDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Mingxiang ZouDepartment of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. zoumingxiang@csu.edu.cn.

Funding

Merck Sharp & Dohme 100759Natural Science Foundation of Hunan Province 2022JJ70084Natural Science Foundation of Hunan Province 2023JJ30900

6 · The paper itself

Abstract

Although ceftazidime-avibactam (CZA) has known effectiveness against carbapenem-resistant Klebsiella pneumoniae (CRKP), its resistance is increasingly being reported. In this study, we explored the mechanisms behind this emerging resistance in CZA-resistant strains generated from 40 clinical K. pneumoniae carbapenemase (KPC)-producing CRKP through in vitro multipassage resistance selection with 1/2 MICs CZA. Of these, 12 strains developed CZA resistance, three of which displayed increased susceptibility to carbapenems, whereas the strain C23 demonstrated heightened susceptibility to tigecycline (TGC) after CZA exposure. bla

Indexed as

Azabicyclo CompoundsBacterial Proteinsbeta-LactamasesBiofilmsCeftazidimeKlebsiella pneumoniaeMutationAnti-Bacterial AgentsDrug CombinationsDrug Resistance, Multiple, BacterialHumansKlebsiella InfectionsMicrobial Sensitivity TestsMutagenesis, InsertionalAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-lactamase KPC-2, Klebsiella pneumoniaebeta-LactamasesCeftazidimeDrug CombinationsCarbapenem-resistant Klebsiella pneumoniaeCeftazidime-avibactamFitness costKPCMechanism of drug resistance

Identifiers

PMID42120625

DOI10.1038/s41598-026-52233-z

PMCPMC13358128

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.